CDKN2A and neoplasm: Resistance to treatment may be due to heightened cyclin E1–CDK2 and PI3K–mTOR signaling in tumor cells lacking CDKN2A, which suggests that other changes can reduce the effectiveness of CDK4/6 inhibitors [28].